– Board Appoints Adam Friedman, M.D., Ph.D., as Interim CEO –
Scorpion Therapeutics announced that Adam Friedman, M.D., Ph.D., has been appointed Chief Executive Officer on an interim basis. The Board of Directors is currently evaluating candidates to lead the Company’s next phase of growth.
“I am humbled by the trust the Board has placed in me and honored to have an opportunity to lead this organization until a permanent CEO is identified,” said Dr. Friedman. “Scorpion Therapeutics has strong momentum with its lead precision oncology programs, multiple discovery platforms, and proven leadership from its veteran R&D team.”
Dr. Friedman was previously a Founder and Director at Raze Therapeutics and, together with Scorpion’s co-founder Keith Flaherty, founder of the oncology platform discovery company Vivid Biosciences, where he served as President and Chief Executive Officer.
Scorpion Therapeutics has secured $270 million in financing since it was founded in the first quarter of 2020, and will continue development of Scorpion’s drug hunting engine, which integrates state-of-the-art capabilities across multiple fields of translational medicine, chemical biology, medicinal chemistry, and data science, as well as the advancement of Scorpion’s growing portfolio, which includes several therapeutic candidates across a range of biological approaches for tumor targeting.